Arcutis Biotherapeutics (ARQT) is up 24.7%, or $4.86 to $24.50.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics reports Q3 EPS 6c, consensus (10c)
- Arcutis Biotherapeutics sees FY26 product revenue $455M-$470M
- Is ARQT a Buy, Before Earnings?
- Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE
- Arcutis Biotherapeutics: Buy Rating Affirmed Amid FDA Approval and Strategic Growth Initiatives
